ABL1 and cancer: Here we report the effects of a family of dual c-Src/c-Abl tyrosine kinase inhibitors with a pyrazolo[3,4-d]-pyrimidine scaffold which we found to be active against different solid tumour cell lines that also express various cancer stem cell markers.